Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.
Chu Y, Muller S, Tavares A, Barret O, Alagille D, Seibyl J, Tamagnan G, Marek K, Luk KC, Trojanowski JQ, Lee VMY, Kordower JH
Injecting abnormal alpha-synuclein into the brain of monkeys causes Parkinson’s-like pathology, including Lewy body-like clumps, loss of dopamine-producing neurons, and changes in brain imaging that mirror early Parkinson’s disease. This model helps study how alpha-synuclein spreads and damages the brain, which may inform treatments for NR4A2-related disorders involving similar pathways.
- Alpha-synuclein injections caused Parkinson’s-like brain changes in monkeys
- Dopamine neurons were reduced by nearly 30% in affected areas
- Lewy body-like clumps formed in brain regions critical for movement
- Brain imaging showed early changes in dopamine systems
- Nurr1, a gene linked to NR4A2, was reduced in damaged neurons
Function of Nr4a Orphan Nuclear Receptors in Proliferation, Apoptosis and Fuel Utilization Across Tissues.
Herring JA, Elison WS, Tessem JS
The Nr4a family of proteins, including NURR1 (NR4A2), plays key roles in controlling cell growth, cell death, and energy use in different tissues. These effects happen through both gene regulation and other rapid cellular mechanisms.
- NR4A2/NURR1 regulates cell growth and survival in multiple tissues
- It influences how cells use energy sources like glucose and fats
- Effects vary by tissue and depend on specific Nr4a family members
- Actions occur through both gene control and non-genomic pathways
- These processes are relevant to neurological and metabolic health
Satb2 is required for the regionalization of retrosplenial cortex.
Zhang L, Song NN, Zhang Q, Mei WY, He CH, Ma P, Huang Y, Chen JY, Mao B, Lang B, Ding YQ
Satb2 is essential for forming the retrosplenial cortex, a brain region involved in memory and navigation, by suppressing genes like Nr4a2 that promote a different brain identity. Without Satb2, the retrosplenial cortex loses its identity and turns into a different brain area. This suggests that NR4A2 overactivity may disrupt brain development in ways relevant to NR4A2-related syndrome.
- Satb2 prevents the retrosplenial cortex from turning into another brain region
- Satb2 suppresses Nr4a2, which if overactive, changes brain cell identity
- NR4A2 misregulation may contribute to brain development issues in NR4A2 syndrome
- This mechanism could explain some neurological symptoms in affected children
Chloroquine modulates inflammatory autoimmune responses through Nurr1 in autoimmune diseases.
Park TY, Jang Y, Kim W, Shin J, Toh HT, Kim CH, Yoon HS, Leblanc P, Kim KS
Chloroquine helps treat autoimmune diseases by boosting Nurr1, a key protein that promotes anti-inflammatory immune cells and reduces harmful immune responses. This effect depends on Nurr1 being activated and made in greater amounts, which chloroquine achieves through two direct mechanisms.
- Chloroquine boosts Nurr1 activity and levels
- Nurr1 drives anti-inflammatory Treg cells
- Chloroquine reduces harmful TH17 cells
- Effect seen in both lab models and IBD mice
- Nurr1 is a promising target for autoimmune therapies
The Basic Helix-Loop-Helix Gene Nato3 Drives Expression of Dopaminergic Neuron Transcription Factors in Neural Progenitors.
Peterson DJ, Marckini DN, Straight JL, King EM, Johnson W, Sarah SS, Chowdhary PK, DeLano-Taylor MK
Nato3 is a gene that can turn on key brain genes needed to make dopamine-producing neurons, including Nurr1 and Lmx1b, in developing neural cells. This suggests Nato3 might help guide stem cells to become dopamine neurons, which could inform future treatments for Parkinson’s disease.
- Nato3 activates genes essential for dopamine neuron development
- It boosts Lmx1b and Nurr1, critical for dopamine neuron formation
- Nato3 works in neural progenitors across different brain regions
- This could help design therapies using stem cells for Parkinson’s
- Findings come from live chick embryo studies, showing real-time effects
Cicadidae Periostracum, the Cast-Off Skin of Cicada, Protects Dopaminergic Neurons in a Model of Parkinson's Disease.
Lim HS, Kim JS, Moon BC, Choi G, Ryu SM, Lee J, Ang MJ, Jeon M, Moon C, Park G
Cicadidae Periostracum (CP) protects dopamine-producing brain cells in a mouse model of Parkinson's disease by boosting Nurr1, reducing brain inflammation, and preventing cell death. CP improved movement and preserved dopamine levels, likely through pathways involving mitochondrial health and immune response.
- CP boosts Nurr1, a key protein for dopamine neuron survival
- CP reduces brain inflammation and prevents neuron death
- CP improves movement and dopamine levels in Parkinson's mice
- CP works by protecting mitochondria and calming immune cells in the brain
Alpha synuclein deficiency increases CD4+ T-cells pro-inflammatory profile in a Nurr1-dependent manner.
Trudler D, Levy-Barazany H, Nash Y, Samuel L, Sharon R, Frenkel D
Alpha-synuclein helps control inflammation in immune cells called CD4+ T-cells, and its absence leads to a more aggressive inflammatory response. This effect is linked to a gene called Nurr1, which becomes overactive when alpha-synuclein is missing, and reducing Nurr1 can calm down the harmful immune response.
- Alpha-synuclein reduces inflammation in CD4+ T-cells
- Without alpha-synuclein, T-cells become more inflammatory
- Nurr1 levels rise when alpha-synuclein is missing
- Turning down Nurr1 reduces harmful cytokines
- This pathway could be a target for new treatments
Pharmacological activation of Nr4a rescues age-associated memory decline.
Chatterjee S, Walsh EN, Yan AL, Giese KP, Safe S, Abel T
Activating the NR4A2 protein with a drug called C-DIM12 improves memory in young mice and restores memory in aged mice, suggesting a potential treatment for age-related memory decline.
- C-DIM12 activates NR4A2, a key brain protein
- It improves memory in young mice
- It reverses memory loss in aged mice
- This suggests a possible therapy for memory decline
Iron Ion-Releasing Polypeptide Thermogel for Neuronal Differentiation of Mesenchymal Stem Cells.
Patel M, Lee HJ, Son S, Kim H, Kim J, Jeong B
An iron-releasing gel scaffold promotes the transformation of stem cells into neuron-like cells, with increased expression of key neuronal markers, including NURR1, suggesting potential for treating neurological conditions involving impaired neuronal development.
- Iron-releasing gel boosts stem cell conversion to neurons
- NURR1 and other neuron markers rise significantly
- Gel supports cell aggregation and survival
- Sustained iron release enhances differentiation
- Potential for injectable therapy in neurodevelopmental disorders
NURR1 Impairment in Multiple Sclerosis.
Montarolo F, Martire S, Perga S, Bertolotto A
NURR1, a protein involved in reducing inflammation and supporting dopamine-producing brain cells, is impaired in multiple sclerosis, where it may help control harmful immune activity in the brain. While not linked to MS through genetic studies, its role in calming brain inflammation suggests it could be a target for new treatments.
- NURR1 reduces brain inflammation in multiple sclerosis
- It protects dopamine-producing neurons
- Low NURR1 may worsen MS symptoms
- It acts in microglia and astrocytes
- Could be a target for future therapies
Dopamine neuron induction and the neuroprotective effects of thyroid hormone derivatives.
Lee EH, Kim SM, Kim CH, Pagire SH, Pagire HS, Chung HY, Ahn JH, Park CH
Thyroid hormone derivatives can effectively turn precursor cells into dopamine neurons and protect them from damage, offering a promising new approach for treating Parkinson's disease, especially since these derivatives avoid the risks of overstimulating thyroid function.
- Thyroid hormone derivatives induce dopamine neurons without overactivating thyroid receptors
- These derivatives protect and restore dopamine neurons from toxic damage
- The process boosts NURR1, a key protein linked to dopamine neuron development
- Results suggest potential for new Parkinson's treatments with fewer side effects
- Findings are based on rat cells but show strong therapeutic promise
Nurr1, Pitx3, and α7 nAChRs mRNA Expression in Nigral Tissue of Rats with Pedunculopontine Neurotoxic Lesion.
Blanco-Lezcano L, Alberti-Amador E, González-Fraguela ME, Larrea GZ, Pérez-Serrano RM, Jiménez-Luna NA, Serrano-Sánchez T, Francis-Turner L, Camejo-Rodriguez D, Vega-Hurtado Y
In rats, damaging the brain's pedunculopontine nucleus leads to early changes in key genes involved in dopamine regulation and nerve signaling in the substantia nigra, suggesting these changes may signal the start of neurodegeneration. The genes Nurr1 and Pitx3 show rapid but temporary shifts, while the α7 nicotinic receptor gene remains suppressed for days.
- PPN injury increases Nurr1 and Pitx3 early on
- Pitx3 drops after initial rise
- α7 nAChR gene stays low for days
- These changes may signal early brain degeneration
- Suggests a chain reaction from brainstem to dopamine areas
Organogermanium suppresses cell death due to oxidative stress in normal human dermal fibroblasts.
Takeda T, Doiyama S, Azumi J, Shimada Y, Tokuji Y, Yamaguchi H, Nagata K, Sakamoto N, Aso H, Nakamura T
THGP, a compound derived from repagermanium, protects human skin cells from oxidative stress damage by reducing cell death and inflammation, not by directly neutralizing free radicals. It works by suppressing genes linked to cell death and inflammation, including NR4A2, which is relevant to neurodevelopmental disorders.
- THGP reduces skin cell death from oxidative stress
- It works by lowering NR4A2, IL6, and CXCL2 gene activity
- Mechanism is not through direct antioxidant action
- NR4A2 suppression is key to its protective effect
- Potential relevance to NR4A2-related syndromes
Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Kandil EA, Sayed RH, Ahmed LA, Abd El Fattah MA, El-Sayeh BM
Albendazole protects brain cells in a rat model of Parkinson's disease by boosting two key proteins, HIF-1α and Nurr1, which support dopamine-producing neurons and reduce brain inflammation and damage. This suggests albendazole could help preserve motor function and slow disease progression.
- Albendazole protects dopamine neurons in a Parkinson's rat model
- It increases levels of Nurr1 and HIF-1α, critical for neuron survival
- It reduces brain inflammation and alpha-synuclein buildup
- It restores dopamine levels and improves movement
- These effects suggest potential for repurposing albendazole in Parkinson's
Inducing Different Neuronal Subtypes from Astrocytes in the Injured Mouse Cerebral Cortex.
Mattugini N, Bocchi R, Scheuss V, Russo GL, Torper O, Lao CL, Götz M
Reprogramming astrocytes into neurons in the injured mouse brain works best when using both Nurr1 and Neurogenin 2, producing neurons that match the brain layer and project correctly. However, this reprogramming fails in white matter, showing that location matters greatly for success.
- Nurr1 + Ngn2 reprogram astrocytes into correct neurons
- Reprogrammed neurons show proper layer and wiring
- Reprogramming fails in white matter regions
- Location and brain layer strongly affect outcomes
Human Trophoblast Differentiation Is Associated With Profound Gene Regulatory and Epigenetic Changes.
Kwak YT, Muralimanoharan S, Gogate AA, Mendelson CR
This study reveals how human placental cells change during development, showing that key genes involved in immune regulation and inflammation are turned off as cells mature into the placental layer that supports the baby. The findings highlight how epigenetic changes, including histone modifications, control this process and may explain problems in placental development linked to preeclampsia.
- Placental cell maturation involves turning off inflammation genes
- NR4A2 (NURR1) is among genes silenced during placental development
- Epigenetic changes regulate immune-related gene activity
- These changes may contribute to preeclampsia and other placental disorders
- Potential targets for treating placental diseases identified
Wnt1 silencing enhances neurotoxicity induced by paraquat and maneb in SH-SY5Y cells.
Huang C, Ma J, Li BX, Sun Y
Wnt1 helps protect dopamine-producing brain cells, and its reduction worsens damage from environmental toxins linked to Parkinson's disease. Lower Wnt1 levels are tied to reduced NURR1 and other key brain factors, suggesting Wnt1 may be a target for treating NR4A2-related disorders.
- Wnt1 loss increases damage from Parkinson's-linked toxins
- Wnt1 reduction lowers NURR1 and dopamine-related proteins
- Wnt1 may protect brain cells during development
- Targeting Wnt1 could help treat NR4A2-related conditions
NURR1 deficiency is associated to ADHD-like phenotypes in mice.
Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A
Mice lacking the NURR1 gene show hyperactivity and impulsive behaviors similar to ADHD, and these symptoms improve with methylphenidate, a common ADHD medication, suggesting NURR1 deficiency may underlie some ADHD-like traits.
- NURR1-deficient mice display ADHD-like hyperactivity and impulsivity
- Methylphenidate reduces hyperactivity in these mice
- No major issues with memory, anxiety, or motor skills were found
- Dopamine levels and neurons remain normal despite behavior changes
- This model may help test new ADHD treatments
Low-dose ionizing radiation attenuates mast cell migration through suppression of monocyte chemoattractant protein-1 (MCP-1) expression by Nr4a2.
Song CH, Joo HM, Han SH, Kim JI, Nam SY, Kim JY
Low-dose radiation reduces mast cell movement by increasing Nr4a2, which lowers levels of MCP-1, a key chemical that attracts immune cells. This effect was seen in lab studies using mast cells, and blocking MCP-1 also stopped migration.
- Low-dose radiation reduces mast cell movement
- Nr4a2 protein controls MCP-1 levels
- MCP-1 blockade stops mast cell migration
- Radiation boosts Nr4a2 to reduce inflammation
- Findings may help manage immune-related symptoms
Neuronal Trans-differentiation by Transcription Factors Ascl1 and Nurr1: Induction of a Dopaminergic Neurotransmitter Phenotype in Cortical GABAergic Neurons.
Raina A, Mahajani S, Bähr M, Kügler S
Scientists successfully converted GABAergic neurons from rat brains into dopamine-producing neurons using two key proteins, Nurr1 and Ascl1. This shows that some mature neurons can be reprogrammed to become dopamine neurons, but only if they were originally GABAergic and not glutamatergic or midbrain-derived. The process works best in neurons with a specific developmental history.
- GABAergic neurons can be turned into dopamine neurons
- Nurr1 plus Ascl1 reprograms neuron identity
- Glutamatergic neurons are harmed by the process
- Midbrain GABA neurons resist reprogramming
- Neuron history determines if reprogramming works
Complementation of dopaminergic signaling by Pitx3-GDNF synergy induces dopamine secretion by multipotent Ntera2 cells.
Eskandarian Boroujeni M, Aliaghaei A, Maghsoudi N, Gardaneh M
This study successfully turned NT2 cells into dopamine-secreting cells by combining Pitx3 gene expression with GDNF signaling, enabling them to survive, integrate, and improve motor function in a Parkinson’s disease rat model. The approach could lead to a cell therapy for Parkinson’s disease using these engineered cells.
- Pitx3 and GDNF together enable NT2 cells to make and release dopamine
- Engineered NT2 cells survive and improve movement in Parkinson’s rats
- The cells show strong neuroprotection against Parkinson’s toxins
- This method may enable clinical use of NT2 cells for Parkinson’s therapy
Conversion of Astrocytes and Fibroblasts into Functional Noradrenergic Neurons.
Li S, Shi Y, Yao X, Wang X, Shen L, Rao Z, Yuan J, Liu Y, Zhou Z, Zhang Z, Liu F, Han S, Geng J, Yang H, Cheng L
Scientists turned non-neuronal cells from human skin and brain into functional noradrenergic neurons using seven key genes. These lab-made neurons behave like real ones, firing signals, connecting to other cells, and even controlling heart cell rhythms. This approach could one day help treat disorders linked to faulty noradrenaline systems.
- Human skin and brain cells can become noradrenergic neurons
- The new neurons act like real ones, sending signals and connecting
- They survive and integrate after transplantation
- This method may help model and treat brain disorders
- Uses seven specific genes to reprogram cells
Heterozygous loss of function of NR4A2 is associated with intellectual deficiency, rolandic epilepsy, and language impairment.
Ramos LLP, Monteiro FP, Sampaio LPB, Costa LA, Ribeiro MDO, Freitas EL, Kitajima JP, Kok F
A new mutation in the NR4A2 gene causes intellectual disability, rolandic epilepsy, and language problems in a child, confirming NR4A2's critical role in neurodevelopment. This finding supports NR4A2 as the key gene behind a specific genetic syndrome.
- NR4A2 mutations cause intellectual disability
- Child has rolandic epilepsy and language issues
- De novo mutation confirms NR4A2's role in neurodevelopment
- Supports NR4A2 as the main gene in 2q23q24 syndrome
- Findings help diagnose and understand the condition
Generation of functional dopaminergic neurons from human spermatogonial stem cells to rescue parkinsonian phenotypes.
Yang H, Hao D, Liu C, Huang D, Chen B, Fan H, Liu C, Zhang L, Zhang Q, An J, Zhao J
Human spermatogonial stem cells can be efficiently turned into functional dopamine-producing neurons that survive, integrate, and improve movement problems in a mouse model of Parkinson's disease, offering a promising new approach for cell therapy.
- hSSCs become dopamine neurons with key markers and function
- Transplanted cells improve Parkinson's symptoms in mice
- No tumors formed after transplantation
- Conversion is efficient and reproducible
- Potential for treating Parkinson's and similar disorders
Characterization of spontaneous spheroids from oral mucosa-derived cells and their direct comparison with spheroids from skin-derived cells.
Li N, Li X, Chen K, Dong H, Kagami H
Oral mucosa cells can form spheroids with strong stem cell and neuron-like potential, outperforming skin-derived cells in key neural markers, suggesting they may be useful for treating nerve-related conditions.
- Oral mucosa cells form spheroids with high stem cell activity
- These spheroids express strong neural markers like Nurr1
- They outperform skin-derived spheroids in neuron-related gene expression
- No special growth factors needed to form spheroids, but they help maintain them
- Potential for regenerating nerve tissue in neurological disorders
In Vivo Direct Reprogramming of Resident Glial Cells into Interneurons by Intracerebral Injection of Viral Vectors.
Pereira M, Birtele M, Rylander Ottosson D
This study shows that glial cells in the brain can be directly converted into functional interneurons using viral vectors carrying specific genes, including Nurr1, which is the same gene mutated in NR4A2-related syndrome. The reprogrammed neurons mature over time, form synapses, and display electrical properties of fast-spiking, parvalbumin-positive interneurons—cell types often affected in neurodevelopmental disorders.
- Glial cells can be turned into interneurons in the living brain
- Nurr1 is key to generating parvalbumin-positive interneurons
- Reprogrammed neurons mature and form functional connections
- The method allows precise tracking and functional testing of new neurons
Nuclear receptor subfamily 4 group A member 2 inhibits activation of ERK signaling and cell growth in response to β-adrenergic stimulation in adult rat cardiomyocytes.
Ashraf S, Hegazy YK, Harmancey R
NR4A2 acts as a natural brake on heart cell growth and stress responses triggered by adrenaline, partly by turning on genes that shut down the ERK growth pathway. This suggests NR4A2 could help protect the heart in conditions like heart failure, but the findings are from rat heart cells, not human patients.
- NR4A2 reduces heart cell growth from adrenaline stress
- It blocks ERK signaling by boosting DUSP2 and DUSP14
- This may protect the heart from damage in chronic stress
- Findings are from rat heart cells, not humans
- Potential for future therapies targeting NR4A2
Early impairment of epigenetic pattern in neurodegeneration: Additional mechanisms behind pyrethroid toxicity.
Bordoni L, Nasuti C, Fedeli D, Galeazzi R, Laudadio E, Massaccesi L, López-Rodas G, Gabbianelli R
Early exposure to permethrin, a common pesticide, disrupts brain development in rats by altering epigenetic patterns and damaging dopamine-producing neurons, which may increase the risk of Parkinson's-like disease later in life. The chemical mimics a natural brain protector (NURR1) and may permanently interfere with gene regulation critical for brain health.
- Permethrin exposure in infancy harms dopamine brain cells
- It alters DNA methylation and gene activity in key brain pathways
- Permethrin binds strongly to NURR1, a protein linked to NR4A2-related disorders
- Changes in gene regulation start in adolescence and may last a lifetime
- This suggests environmental toxins could worsen or trigger NR4A2-related conditions
Pyrethroid exposure and neurotoxicity: a mechanistic approach.
Mohammadi H, Ghassemi-Barghi N, Malakshah O, Ashari S
Exposure to common household insecticides called pyrethroids can harm the nervous system by damaging brain cells, disrupting mitochondria, and causing inflammation, with effects similar to those seen in Parkinson's disease. These chemicals interfere with key protective pathways like Nurr1, which is also linked to NR4A2-related syndrome, suggesting environmental factors may worsen neurological symptoms in affected children.
- Pyrethroids harm brain cells and disrupt nerve function
- They impair protective pathways like Nurr1, relevant to NR4A2 syndrome
- Mitochondrial damage and inflammation are major mechanisms
- These effects mirror Parkinson's disease processes
- Reducing exposure may help protect neurological health
Developmental Dieldrin Exposure Alters DNA Methylation at Genes Related to Dopaminergic Neuron Development and Parkinson's Disease in Mouse Midbrain.
Kochmanski J, VanOeveren SE, Patterson JR, Bernstein AI
Exposure to the pesticide dieldrin during development alters DNA methylation in mouse brains, particularly at genes critical for dopamine neuron development like NR4A2 and LMX1B. These changes create lasting, sex-specific epigenetic shifts that may increase vulnerability to neurodegenerative diseases like Parkinson’s later in life.
- Dieldrin exposure alters DNA methylation in developing mouse brains
- NR4A2 and LMX1B genes show methylation changes linked to dopamine neurons
- Changes are sex-specific and may increase Parkinson’s risk later in life
- Epigenetic changes may make neurons more sensitive to toxins
- Findings suggest early environmental exposures can affect long-term brain health
Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease.
Malanda A, Abécassis PY, Barnéoud P, Brunel P, Taupin V, Vigé X, Lesuisse D
These new drugs activate the NURR1 protein, which is essential for brain cells that are lost in Parkinson's disease. The compounds show promising properties for reaching the brain and safety in early tests, supporting their potential use in treating Parkinson's.
- Drugs activate NURR1, a key protein in Parkinson's
- Compounds reach the brain and show good safety in early tests
- Designed to protect dopamine-producing brain cells
- Supports development of new Parkinson's treatments
Activation of Peroxisome Proliferator-Activated Receptor-α Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons.
Gottschalk CG, Roy A, Jana M, Kundu M, Pahan K
Activating PPARα with the drug gemfibrozil increases Nurr1 levels in dopamine-producing brain cells, which may protect them from damage. This effect depends on PPARα, as it does not occur when PPARα is missing.
- PPARα activation boosts Nurr1 in dopamine neurons
- Gemfibrozil increases Nurr1 in mouse brains
- Nurr1 is critical for healthy dopamine neurons
- PPARα is a direct regulator of Nurr1 gene expression
- This pathway could protect against Parkinson’s-like damage
NURR1 activation in skeletal muscle controls systemic energy homeostasis.
Amoasii L, Sanchez-Ortiz E, Fujikawa T, Elmquist JK, Bassel-Duby R, Olson EN
Activating NURR1 in muscle improves glucose control and energy use in mice, mimicking exercise benefits and suggesting potential treatments for metabolic issues like obesity and diabetes.
- NURR1 in muscle boosts glucose uptake and storage
- NURR1 activation improves exercise performance
- NURR1 drugs mimic exercise effects in obese mice
- NURR1 may help treat metabolic diseases
Transplantation of Nurr1-overexpressing neural stem cells and microglia for treating parkinsonian rats.
Qian Y, Chen XX, Wang W, Li JJ, Wang XP, Tang ZW, Xu JT, Lin H, Yang ZY, Li LY, Song XB, Guo JZ, Bian LG, Zhou L, Lu D, Deng XL
Transplanting neural stem cells and microglia that overexpress the Nurr1 gene improves movement symptoms in Parkinson's disease rats, increases dopamine-producing cells in the brain, and helps the transplanted cells survive long-term. This approach makes the brain environment more supportive for cell therapy.
- Nurr1-overexpressing cells improve Parkinson's symptoms in rats
- More dopamine neurons survive and function after transplant
- Reduced brain inflammation after combined cell therapy
- Transplanted cells remain active for at least 5 months
- A promising strategy for future Parkinson's cell therapy
Multiple pathways for natural product treatment of Parkinson's disease: A mini review.
Li J, Long X, Hu J, Bi J, Zhou T, Guo X, Han C, Huang J, Wang T, Xiong N, Lin Z
Natural products may protect dopamine-producing brain cells in Parkinson's disease by targeting multiple pathways, including preventing cell death, reducing inflammation, and boosting dopamine signaling. One natural compound was found to directly bind to a key protein involved in these protective processes.
- Natural products protect brain cells by reducing cell death
- They reduce brain inflammation and oxidative stress
- They boost dopamine production and signaling
- A natural compound binds directly to a protective protein
- These findings suggest combination therapies may help slow Parkinson's
Inhibition of Ezh2 In Vitro and the Decline of Ezh2 in Developing Midbrain Promote Dopaminergic Neurons Differentiation Through Modifying H3K27me3.
Hong F, Zhao M, Zhang L, Feng L
Reducing Ezh2 activity helps brain cells that make dopamine develop better, especially in the midbrain region, by removing a molecular brake on dopamine neuron formation. This effect depends on Nurr1, a gene linked to NR4A2-related syndrome, suggesting a potential pathway for treatment.
- Blocking Ezh2 boosts dopamine neuron development
- Ezh2 reduction lowers H3K27me3, a gene-silencing mark
- Nurr1 is essential for this process to work
- This mechanism occurs in both lab and developing brain tissue
- May inform therapies targeting NR4A2/Nurr1 pathways
Neonatal Nicotine Exposure Primes Midbrain Neurons to a Dopaminergic Phenotype and Increases Adult Drug Consumption.
Romoli B, Lozada AF, Sandoval IM, Manfredsson FP, Hnasko TS, Berg DK, Dulcis D
Early nicotine exposure in mice reprograms brain cells to become dopamine-producing, making them more likely to seek drugs as adults. This change happens when brain cells first become sensitive to a key protein (Nurr1) and then switch to a dopamine-producing state when exposed to nicotine again later in life.
- Neonatal nicotine exposure reprograms brain cells
- Cells gain dopamine-producing ability in adulthood
- Nurr1 protein is essential for this change
- Altered brain activity increases drug-seeking behavior
- This may explain heightened addiction risk after early exposure